Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus endocrine therapy vs chemotherapy followed by endocrine therapy in high-risk HR+/HER2- metastatic breast cancer
ChiCTR2500113953Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dalpiciclib in breast cancer (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500113953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113953.